A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
about
Clinical management of localized colon cancer with capecitabineCapecitabine in the management of colorectal cancerA tailored nurse coaching intervention for oral chemotherapy adherenceOral drugs in the treatment of metastatic colorectal cancer.Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancerAcceptance of oral chemotherapy in breast cancer patients - a survey study.Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tabletsCritical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerationsMeta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trialA randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features.Safe practice and nursing care of patients receiving oral anti-cancer medicines: a position statement from UKONS.Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool.Management of advanced colorectal cancer: state of the art.A review of the role of capecitabine in the treatment of colorectal cancer.Capecitabine in advanced gastric cancer.Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients.Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.Preferences for oral versus intravenous adjuvant chemotherapy among early breast cancer patients.Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design.Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.Radiation therapy for rectal cancer: current status and future directions.Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial.XELOX in colorectal cancer: a convenient option for the future?Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain.Real-world resource use and costs of adjuvant treatment for stage III colon cancer.Preferences of colorectal cancer patients for treatment and decision-making: a systematic literature review.Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?Oral versus intravenous fluoropyrimidines for colorectal cancer.Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer.Protons offer reduced bone marrow, small bowel, and urinary bladder exposure for patients receiving neoadjuvant radiotherapy for resectable rectal cancer.Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada.A phase II trial of preoperative concurrent chemotherapy and dose escalated intensity modulated radiotherapy (IMRT) for locally advanced rectal cancer.
P2860
Q24611758-7E458D69-9E81-4733-8D70-32AB29237E68Q24633039-15E1D67B-E3D3-4C98-B841-B8B1AA45406DQ27013626-CCCCD7E0-74A7-469A-8A9A-9D4E2DB60ABEQ30251387-22B3D8FB-B200-4D79-AB98-056EF6DFAC8AQ33374960-85949823-B8DC-41FD-AF08-BE964B147A3FQ33398998-16381964-807D-4265-8CFA-C08CC0C9CA1AQ33620052-106CFF07-A357-4E3F-B6F8-D2A96E4768B9Q33870472-FC2F102C-482E-4B46-A9AA-E4FDE2C3FCBDQ34133316-7ED982A7-92E2-4A76-BEC1-6DDA86D27EC2Q34418437-2788E123-6A8C-4BF3-8AC4-A56F23E3ECFFQ34608222-CE3F2DF3-E0AF-40B6-AFF1-AC3562912121Q34609932-E9ECFF13-57E8-4B81-95A4-F66F7D0B31EFQ34622205-A2ED6914-3F45-45AE-99CE-97941B0C7A81Q35129364-12E02B86-A8ED-4FBE-A256-5D816D7ECDA4Q35602151-5C3BCC0A-EBD7-4A6F-AEDB-91A98971D627Q35663058-9ABBC900-55F4-4082-A7DF-082FEC227EB8Q36533867-1AABF626-BA16-4E48-8B22-B0C7FCF3FF88Q36661290-733A7AE5-C0B8-47E4-B992-955484740913Q36979346-F4FB6CFD-0DA7-429C-B635-EA25820227B5Q37122339-252D8C2C-6382-4B79-865E-C3BF8C8DD14DQ37269696-DEEB198D-B7CD-4821-AA90-61F425071DFEQ37341013-AE546B76-B120-4588-96AE-92C639EA6128Q37367023-3A5045E9-3C82-46A4-BEAD-713CACFD9703Q37400585-70078E10-C153-4EEC-A48E-8E9069761FB0Q37513062-2795C3F0-FC27-40B0-A370-077C6DF7ACCFQ37654670-4F5354F7-6AD2-4352-AC51-3E700D1DC782Q37669505-C654090F-5A80-408B-9AF1-DA735D3F4C69Q37839084-0528F7B6-B4D0-405F-9EDF-8B6D2B21226FQ37962660-E4A108FA-EC90-49FA-A822-A94EBA5BE832Q38174218-C4F3F068-4D6C-4F4B-8B94-96A75FEC0697Q38212819-50243E77-A99E-4CFC-9647-748327871BC2Q38216008-1492C4DA-995A-4A8B-A220-33BA52B48309Q38650502-232B2C1C-C249-4573-8B05-07B9BA5E4939Q39153086-46ACA8F1-586D-4113-9DED-89971C53E94BQ39786290-EBCAD97F-A356-4F4C-AA87-51C179DA30DFQ41559464-66647A71-CB46-4510-897A-212F788FD340Q41894910-B278E0FD-34EC-49B4-A10C-56E365143140Q43077120-4FC1954A-EEAC-4115-8D8A-179DF7718ABBQ44802035-F2C36241-75DD-43C6-8E7D-1AB8393BDA2CQ47126907-F97F6B02-8097-41AB-9100-B6187CD862DB
P2860
A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
A randomised cross-over trial ...... th advanced colorectal cancer.
@en
A randomised cross-over trial ...... th advanced colorectal cancer.
@nl
type
label
A randomised cross-over trial ...... th advanced colorectal cancer.
@en
A randomised cross-over trial ...... th advanced colorectal cancer.
@nl
prefLabel
A randomised cross-over trial ...... th advanced colorectal cancer.
@en
A randomised cross-over trial ...... th advanced colorectal cancer.
@nl
P2093
P2860
P356
P1433
P1476
A randomised cross-over trial ...... th advanced colorectal cancer.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDJ023
P577
2005-12-12T00:00:00Z